Literature DB >> 14580717

The N-terminus of human prolactin modulates its biological properties.

Sophie Bernichtein1, Jean-Baptiste Jomain, Paul A Kelly, Vincent Goffin.   

Abstract

The N-terminus is the most divergent region within the prolactin (PRL)/placental lactogen (PL)/growth hormone (GH) family. Since all of these ligands are able to activate the lactogen receptor, it has been usually assumed that the N-terminus plays no major role in biological actions of any family member. In this study, we generated several analogs of human PRL in which the N-terminus was truncated by 9 and iteratively up to the 14 first residues. Truncation did not alter protein folding, and it even decreased the formation of PRL aggregates that appear during the purification of refolded protein. Removal of the entire N-terminal loop (14 residues) decreased the affinity for the receptor by two-three-fold, and reduced the ability of the hormone to activate the human lactogen receptor. In contrast, removal of 13 or less residues improves receptor activation since these analogs are able to produce supra-maximal activities in a transcriptional bioassay, or in proliferation assays exhibit dose-response curves that are less bell-shaped, which reflects enhanced stabilization of receptor dimers. Altogether, these data suggest that the N-terminus of PRL is actually slightly detrimental to bioactivity, but may be required for other properties of the hormone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14580717     DOI: 10.1016/s0303-7207(03)00264-8

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  8 in total

1.  Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2.

Authors:  Isabelle Broutin; Jean-Baptiste Jomain; Estelle Tallet; Jan van Agthoven; Bertrand Raynal; Sylviane Hoos; Birthe B Kragelund; Paul A Kelly; Arnaud Ducruix; Patrick England; Vincent Goffin
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

Review 2.  Rational design of competitive prolactin/growth hormone receptor antagonists.

Authors:  Estelle Tallet; Vincent Rouet; Jean-Baptiste Jomain; Paul A Kelly; Sophie Bernichtein; Vincent Goffin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

Review 3.  Development of new prolactin analogs acting as pure prolactin receptor antagonists.

Authors:  Vincent Goffin; Sophie Bernichtein; Christine Kayser; Paul A Kelly
Journal:  Pituitary       Date:  2003-09       Impact factor: 4.107

4.  Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells.

Authors:  Fransiscus E Utama; Thai H Tran; Amy Ryder; Matthew J LeBaron; Albert F Parlow; Hallgeir Rui
Journal:  Endocrinology       Date:  2008-11-20       Impact factor: 4.736

Review 5.  Molecular mechanisms of prolactin and its receptor.

Authors:  Charles L Brooks
Journal:  Endocr Rev       Date:  2012-05-10       Impact factor: 19.871

6.  An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation.

Authors:  Shengze Yu; Amira Alkharusi; Gunnar Norstedt; Torbjörn Gräslund
Journal:  PLoS One       Date:  2019-05-07       Impact factor: 3.240

7.  Short prolactin isoforms are expressed in photoreceptors of canine retinas undergoing retinal degeneration.

Authors:  Raghavi Sudharsan; Leonardo Murgiano; Hsin-Yao Tang; Timothy W Olsen; Venkata R M Chavali; Gustavo D Aguirre; William A Beltran
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

8.  Periplasmic synthesis and purification of the human prolactin antagonist Δ1-11-G129R-hPRL.

Authors:  Miriam F Suzuki; Larissa A Almeida; Stephanie A Pomin; Felipe D Silva; Renan P Freire; João E Oliveira; Regina Affonso; Carlos R J Soares; Paolo Bartolini
Journal:  AMB Express       Date:  2021-04-27       Impact factor: 3.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.